An NYU Langone Health study establishes sacituzumab tirumotecan after immunotherapy as a new standard treatment in recurrent ...
NYU Langone welcomes Ishwaria Subbiah, MD, to lead cancer symptom management at Perlmutter Cancer Center. Learn more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results